cagrilintide clinical trials New in the August 14, 2025, issue of NEJM: Cagrilintide–Semaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial) Cagrilintide–Semaglutide for Overweight and Diabetes (REDEFINE 2 phase 3a trial) Novo Nordisk: Can CagriSema Show
Pay in 4 interest-free payments of $5.97 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6

01022-6/asset/3f55ea20-b36b-4e11-88e9-940a60e8677e/main.assets/gr2_lrg.jpg)























